1. Home
  2. SYBX vs OXBR Comparison

SYBX vs OXBR Comparison

Compare SYBX & OXBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Synlogic Inc.

SYBX

Synlogic Inc.

N/A

Current Price

$1.10

Market Cap

15.2M

Sector

Health Care

ML Signal

N/A

Logo Oxbridge Re Holdings Limited

OXBR

Oxbridge Re Holdings Limited

HOLD

Current Price

$1.44

Market Cap

11.0M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
SYBX
OXBR
Founded
N/A
2013
Country
United States
Cayman Islands
Employees
N/A
3
Industry
Biotechnology: Pharmaceutical Preparations
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
15.2M
11.0M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
SYBX
OXBR
Price
$1.10
$1.44
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$5.00
AVG Volume (30 Days)
67.2K
17.3K
Earning Date
11-13-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,423,000.00
Revenue This Year
N/A
$497.99
Revenue Next Year
N/A
$42.14
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.90
$1.12
52 Week High
$1.96
$5.81

Technical Indicators

Market Signals
Indicator
SYBX
OXBR
Relative Strength Index (RSI) 26.78 49.71
Support Level $1.01 $1.38
Resistance Level $1.20 $1.48
Average True Range (ATR) 0.09 0.07
MACD -0.03 0.02
Stochastic Oscillator 13.89 60.47

Price Performance

Historical Comparison
SYBX
OXBR

About SYBX Synlogic Inc.

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

About OXBR Oxbridge Re Holdings Limited

Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer. It provides reinsurance solutions through its subsidiary. It focuses on underwriting fully collateralized reinsurance contracts for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. Oxbridge specializes in underwriting medium frequency, high severity risks, where insufficient data exists to analyze effectively the risk/return profile of reinsurance contracts. The company manages its business on the basis of one operating segment, Property and Casualty Reinsurance.

Share on Social Networks: